Recombinant adenoviruses carrying transgenes
Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.
1. A recombinant adenovirus comprising a nucleotide sequence inserted in an IX-E2 insertion site, wherein the IX-E2 insertion site is located between the stop codon of adenovirus IX gene and the stop codon of adenovirus IVa2 gene, wherein the nucleotide sequence comprises a promoter, a transgene, and a second polyadenylation signal and the recombinant adenovirus comprises in a 5′ to 3′ orientation:
(i) a first polyadenylation signal;
(ii) a fourth polyadenylation signal;
(iii) the promoter;
(iv) the transgene;
(v) the second polyadenylation signal; and
(vi) a third polyadenylation signal;
wherein the transgene is operably linked to the promoter,
wherein the second polyadenylation signal is the polyadenylation signal of the transgene, and
wherein the fourth polyadenylation signal is in the opposite transcriptional direction of the first polyadenylation signal.
2. The recombinant adenovirus of claim 1 , wherein the nucleotide sequence is inserted between nucleotides corresponding to 4029 and 4093 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides corresponding to 3899 and 3970 of the Ad35 genome (SEQ ID NO: 41).
3. The recombinant adenovirus of claim 1 , wherein the first polyadenylation signal comprises the polyadenylation signal of the IX gene and the third polyadenylation signal is the polyadenylation signal of the adenovirus IVa2 gene.
4. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an E1b-19K insertion site, an E3 insertion site, or an E4 insertion site.
5. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus further comprises a nucleotide sequence inserted in an L5-E4 insertion site, wherein the L5-E4 insertion site is located between the stop codon of adenovirus fiber gene and the stop codon of ORF6 or ORF6/7 of adenovirus E4 gene.
6. The recombinant adenovirus of claim 1 , wherein the recombinant adenovirus is capable of selectively replicating in a hyperproliferative cell.
7. The recombinant adenovirus of claim 3 , wherein the recombinant adenovirus is capable of selectively expressing the transgene in a hyperproliferative cell.
8. A recombinant adenovirus comprising a first nucleotide sequence inserted in an IX-E2 insertion site and a second nucleotide sequence inserted in an L5-E4 insertion site, wherein the IX-E2 insertion site is located between the stop codon of adenovirus IX gene and the stop codon of adenovirus IVa2 gene, and wherein the L5-E4 insertion site is located between the stop codon of adenovirus fiber gene and the stop codon of ORF6 or ORF6/7 of adenovirus E4 gene, wherein the first nucleotide sequence comprises a first promoter, a first transgene, and a third polyadenylation signal and the recombinant adenovirus comprises in a 5′ to 3′ orientation:
(i) a first polyadenylation signal;
(ii) a fourth polyadenylation signal;
(iii) the first promoter;
(iv) the first transgene;
(v) the second polyadenylation signal; and
(vi) a third polyadenylation signal;
wherein the first transgene is operably linked to the first promoter,
wherein the second polyadenylation signal is the polyadenylation signal of the first transgene, and
wherein the fourth polyadenylation signal is in the opposite transcriptional direction of the first polyadenylation signal.
9. The recombinant adenovirus of claim 8 , wherein the first nucleotide sequence is inserted between nucleotides corresponding to 4029 and 4093 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides corresponding to 3899 and 3970 of the Ad35 genome (SEQ ID NO: 41).
10. The recombinant adenovirus of claim 8 , wherein the second nucleotide sequence is inserted between nucleotides corresponding to 32785 to 32916 of the Ad5 genome (SEQ ID NO: 1) or between nucleotides corresponding to 31799 and 31821 of the Ad35 genome (SEQ ID NO: 41).
11. The recombinant adenovirus of claim 8 , wherein the first polyadenylation signal is the polyadenylation signal of the IX gene and the third polyadenylation signal is the polyadenylation signal of the adenovirus IVa2 gene.
12. The recombinant adenovirus of claim 8 , wherein the second nucleotide sequence comprises a second promoter, a second transgene, and a sixth polyadenylation signal and the recombinant adenovirus comprises, in a 5′ to 3′ orientation:
(i) a fifth polyadenylation signal;
(ii) the second promoter;
(iii) the second transgene;
(iv) the sixth polyadenylation signal; and
(v) a seventh polyadenylation signal;
wherein the second transgene is operably linked to the second promoter, and
wherein the sixth polyadenylation signal is the polyadenylation signal of the second transgene.
13. The recombinant adenovirus of claim 12 , wherein the fifth polyadenylation signal is the polyadenylation signal of the fiber (L5) gene and the seventh polyadenylation signal is the polyadenylation signal of the ORF6 or ORF6/7 of the adenovirus E4 gene.
14. The recombinant adenovirus of claim 12 , further comprising an eighth polyadenylation signal between the fifth polyadenylation signal and the second promoter, wherein the eighth polyadenylation signal is in the opposite transcriptional direction of the fifth polyadenylation signal.
15. The recombinant adenovirus of claim 8 , wherein the recombinant adenovirus further comprises a third nucleotide sequence inserted in an E1b-19K insertion site, an E3 insertion site, or an E4 insertion site.
16. The recombinant adenovirus of claim 8 , wherein the recombinant adenovirus is capable of selectively replicating in a hyperproliferative cell.
17. The recombinant adenovirus of claim 12 , wherein the recombinant adenovirus is capable of selectively expressing the first transgene and the second transgene in a hyperproliferative cell.